Table 5. Univariate analysis of predictive factors for TEE in patients with GCT.
| Characteristics | Number of TEE | P | Relative risk |
|---|---|---|---|
| Age (years) | |||
| ⩽30 | 3 | 0.001 | 1 |
| >30 | 16 | 6.8 | |
| Weight (kg) | |||
| ⩽70 | 3 | 0.002 | 1 |
| >70 | 16 | 5.5 | |
| Body surface area (m2) | |||
| ⩽1.9 | 5 | 0.01 | 1 |
| >1.9 | 14 | 3.4 | |
| Performance status (WHO) | |||
| 0–1 | 17 | 0.31 | |
| 2–3 | 2 | ||
| Histology | |||
| Pure seminoma | 6 | 0.01 | 3.4 |
| NSGCT | 13 | 1 | |
| Primary tumour site | |||
| Testis | 16 | 0.7 | |
| Extragonadal | 3 | ||
| IGCCCG classification | |||
| Good | 10 | 0.36 | |
| Intermediate or poor | 7 | ||
| Stage before chemotherapy | |||
| Stage I | 2 | 0.63 | |
| Stage II | 9 | ||
| Stage III | 8 | ||
| Maximal tumour diameter (mm) | |||
| ⩽40 | 4 | 0.15 | |
| >40 | 8 | ||
| Central venous catheter | |||
| Yes | 11 | 0.14 | |
| No | 8 | ||
| Febrile neutropenia | |||
| Yes | 6 | 0.09 | 2.2 |
| No | 13 | 1 | |
| Preventive anticoagulant therapy | |||
| Yes | 4 | 0.15 | |
| No | 15 | ||
| Alkaline phosphatase | |||
| Normal | 16 | 0.00001 | 1 |
| Elevated | 3 | 14.5 | |
| PT, APTT | |||
| Norma | 13 | 0.08 | 1 |
| Abnormal | 6 | 2.3 | |
| LDH | |||
| Normal | 5 | 0.01 | 1 |
| Elevated | 14 | 4.6 |
NSGCT=nonseminous germ-cell tumours; TEE=thrombo-embolic events; LDH=lactate dehydrogenase; PT=prothrombine time; APTT=activated partial thromboplastin time.